In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.
AUTOR(ES)
Hofflin, J M
RESUMO
We investigated the activity of roxithromycin (RU 965) and gamma interferon alone and in combination in a murine model of toxoplasmic encephalitis. Roxithromycin at a dosage of 35 or 50 mg per mouse per day decreased mortality. Gamma interferon alone significantly prolonged time to death. When combined, the two agents were remarkably synergistic.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174724Documentos Relacionados
- Activity of roxithromycin (RU 28965), a macrolide, against Toxoplasma gondii infection in mice.
- Roxithromycin (RU 965): effective therapy for experimental syphilis infection in rabbits.
- Entry of roxithromycin (RU 965), imipenem, cefotaxime, trimethoprim, and metronidazole into human polymorphonuclear leukocytes.
- Antimicrobial activity of U-70138F (paldimycin), roxithromycin (RU 965), and ofloxacin (ORF 18489) against Chlamydia trachomatis in cell culture.
- Rifapentine is active in vitro and in vivo against Toxoplasma gondii.
